Cogent Biosciences/$COGT
Cogent Biosciences shares are trading higher after its drug bezuclastinib achieved primary and key secondary endpoints in a Phase III systemic mastocytosis study.
7 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cogent Biosciences
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Ticker
$COGT
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
205
ISIN
US19240Q2012
Website
COGT Metrics
BasicAdvanced
$1.1B
-
-$2.04
0.22
-
Price and volume
Market cap
$1.1B
Beta
0.22
52-week high
$12.11
52-week low
$3.72
Average daily volume
3.2M
Financial strength
Current ratio
5.128
Quick ratio
4.981
Long term debt to equity
7.069
Total debt to equity
7.804
Profitability
EBITDA (TTM)
-285.977
Management effectiveness
Return on assets (TTM)
-47.45%
Return on equity (TTM)
-84.04%
Valuation
Price to book
9.61
Price to tangible book (TTM)
9.61
Price to free cash flow (TTM)
-5.55
Free cash flow yield (TTM)
-18.02%
Free cash flow per share (TTM)
-168.47%
Growth
Earnings per share change (TTM)
-40.39%
3-year earnings per share growth (CAGR)
-2.65%
What the Analysts think about COGT
Analyst ratings (Buy, Hold, Sell) for Cogent Biosciences stock.
Bulls say / Bears say
Cogent Biosciences' lead product, bezuclastinib, is in a Phase 3 trial targeting KIT mutations in systemic mastocytosis and gastrointestinal stromal tumors, indicating significant market potential. (directorstalkinterviews.com)
Analysts have set an average 12-month price target of $16.20 for COGT, suggesting a potential upside of over 100% from its current price. (indmoney.com)
The company has a diversified pipeline, including CGT4859, a selective FGFR2 inhibitor in Phase 1 trials, expanding its therapeutic reach. (stocktitan.net)
Cogent Biosciences operates at a loss, with a negative EPS of -1.97 and a return on equity of -84.04%, reflecting financial instability. (directorstalkinterviews.com)
The company's P/E ratio is -3.92, indicating negative earnings and potential challenges in achieving profitability. (marketbeat.com)
Despite a consensus 'Moderate Buy' rating, some analysts have downgraded the stock to 'Hold', reflecting mixed sentiments. (defenseworld.net)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
COGT Financial Performance
Revenues and expenses
COGT Earnings Performance
Company profitability
COGT News
AllArticlesVideos
Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock
GlobeNewsWire·5 hours ago
Why Is Cogent Biosciences Stock Trading Higher On Monday?
Benzinga·2 days ago
Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis
GlobeNewsWire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cogent Biosciences stock?
Cogent Biosciences (COGT) has a market cap of $1.1B as of July 09, 2025.
What is the P/E ratio for Cogent Biosciences stock?
The price to earnings (P/E) ratio for Cogent Biosciences (COGT) stock is 0 as of July 09, 2025.
Does Cogent Biosciences stock pay dividends?
No, Cogent Biosciences (COGT) stock does not pay dividends to its shareholders as of July 09, 2025.
When is the next Cogent Biosciences dividend payment date?
Cogent Biosciences (COGT) stock does not pay dividends to its shareholders.
What is the beta indicator for Cogent Biosciences?
Cogent Biosciences (COGT) has a beta rating of 0.22. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.